MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis
In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional...
Gespeichert in:
| Veröffentlicht in: | Neurosurgical review 2024-11, Vol.47 (1), p.835, Article 835 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 835 |
| container_title | Neurosurgical review |
| container_volume | 47 |
| creator | Musmar, Basel Salim, Hamza Adel Grory, Brian Mac Musmar, Fares Spellicy, Samantha Abdelgadir, Jihad Adeeb, Nimer Hasan, David |
| description | In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional outcomes, mortality rates, and the presence of atrial fibrillation (Afib). A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, following PRISMA guidelines. The search strategy employed a combination of keywords and index terms including “Acute Ischemic Stroke,” “AIS,” “Cerebral Infarction,” “Atrial Fibrillation,” “AFib,” “stroke,” “MR-proANP,” “Mid-regional pro-atrial natriuretic peptide,” and “proatrial natriuretic peptide.” Inclusion criteria encompassed any study focusing on MR-proANP and ischemic stroke, published up to October 15, 2023. Primary end points were newly diagnosed Afib, 90-day Modified Rankin Scale (mRS) score, and 90-day mortality. Studies were described in narrative and tabular form. Risk of bias was assessed using the ROBINS-I tool. Pooled estimates for our key end points were generated using a random effects model where appropriate. MR-proANP levels were significantly elevated in newly diagnosed Afib patients compared to no Afib patients (mean difference (MD): 134.4 pmol/l; 95% confidence interval (CI): 119.45 to 149.35,
P
|
| doi_str_mv | 10.1007/s10143-024-03073-w |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3124124952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3124124952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1791-dea93000fbf18235d8b1c3ed22428f5821c9ceeeb635c5c392b56adb5360c93</originalsourceid><addsrcrecordid>eNp9kMlOwzAQhi0EomV5AQ7IRy4GL1m5VRWbVBYBd8txJpCSpXiSVn17TFMQJyRLY3m--eX5CDkR_FxwHl-g4CJQjMuAccVjxVY7ZOxfYiaV5Lt_7iNygDjnXMQpF_tkpNIgjZJAjUlx_8wWrp08PNEKllAhLRs6sX0HtET7DnVpKXau_QBqmpzaqmxKayra9p1ta8BLaiiusYPadB51sCxhtUFr6AwzjanWWOIR2StMhXC8rYfk5frqdXrLZo83d9PJjFn_NcFyMKninBdZIRKpwjzJhFWQSxnIpAgTKWxqASCLVGhDq1KZhZHJs1BF3KbqkJwNqX6jzx6w07VfAqrKNND2qJWQgT9pKD0qB9S6FtFBoReurI1ba8H1t1092NXert7Y1Ss_dLrN77Ma8t-RH50eUAOAvtW8gdPztnfeAf4X-wXgAoY6</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3124124952</pqid></control><display><type>article</type><title>MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Musmar, Basel ; Salim, Hamza Adel ; Grory, Brian Mac ; Musmar, Fares ; Spellicy, Samantha ; Abdelgadir, Jihad ; Adeeb, Nimer ; Hasan, David</creator><creatorcontrib>Musmar, Basel ; Salim, Hamza Adel ; Grory, Brian Mac ; Musmar, Fares ; Spellicy, Samantha ; Abdelgadir, Jihad ; Adeeb, Nimer ; Hasan, David</creatorcontrib><description>In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional outcomes, mortality rates, and the presence of atrial fibrillation (Afib). A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, following PRISMA guidelines. The search strategy employed a combination of keywords and index terms including “Acute Ischemic Stroke,” “AIS,” “Cerebral Infarction,” “Atrial Fibrillation,” “AFib,” “stroke,” “MR-proANP,” “Mid-regional pro-atrial natriuretic peptide,” and “proatrial natriuretic peptide.” Inclusion criteria encompassed any study focusing on MR-proANP and ischemic stroke, published up to October 15, 2023. Primary end points were newly diagnosed Afib, 90-day Modified Rankin Scale (mRS) score, and 90-day mortality. Studies were described in narrative and tabular form. Risk of bias was assessed using the ROBINS-I tool. Pooled estimates for our key end points were generated using a random effects model where appropriate. MR-proANP levels were significantly elevated in newly diagnosed Afib patients compared to no Afib patients (mean difference (MD): 134.4 pmol/l; 95% confidence interval (CI): 119.45 to 149.35,
P
< 0.0001). Unfavorable functional outcomes, as measured by mRS scores of ≥ 3 at 90 days, were associated with higher levels of MR-proANP (MD: 93.87 pmol/; 95% CI: 76.66 to 111.09,
P
< 0.0001). Elevated MR-proANP levels were also strongly correlated with increased 90-day mortality rates (MD: 164.43 pmol/; CI: 95.94 to 232.92,
P
< 0.0001). MR-proANP was significantly associated with functional outcomes, 90-day mortality, and the newly diagnosed AF. The limited number of studies included calls for further large-scale research to confirm these findings and explore the potential for expedited diagnostic procedures and targeted interventions like anticoagulant therapy.</description><identifier>ISSN: 1437-2320</identifier><identifier>EISSN: 1437-2320</identifier><identifier>DOI: 10.1007/s10143-024-03073-w</identifier><identifier>PMID: 39496843</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Atrial Fibrillation - blood ; Atrial Natriuretic Factor - blood ; Biomarkers - blood ; Brain Ischemia - blood ; Brain Ischemia - diagnosis ; Humans ; Ischemic Stroke - blood ; Ischemic Stroke - diagnosis ; Medicine ; Medicine & Public Health ; Neurosurgery ; Prognosis</subject><ispartof>Neurosurgical review, 2024-11, Vol.47 (1), p.835, Article 835</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1791-dea93000fbf18235d8b1c3ed22428f5821c9ceeeb635c5c392b56adb5360c93</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10143-024-03073-w$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10143-024-03073-w$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,782,786,27931,27932,41495,42564,51326</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39496843$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Musmar, Basel</creatorcontrib><creatorcontrib>Salim, Hamza Adel</creatorcontrib><creatorcontrib>Grory, Brian Mac</creatorcontrib><creatorcontrib>Musmar, Fares</creatorcontrib><creatorcontrib>Spellicy, Samantha</creatorcontrib><creatorcontrib>Abdelgadir, Jihad</creatorcontrib><creatorcontrib>Adeeb, Nimer</creatorcontrib><creatorcontrib>Hasan, David</creatorcontrib><title>MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis</title><title>Neurosurgical review</title><addtitle>Neurosurg Rev</addtitle><addtitle>Neurosurg Rev</addtitle><description>In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional outcomes, mortality rates, and the presence of atrial fibrillation (Afib). A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, following PRISMA guidelines. The search strategy employed a combination of keywords and index terms including “Acute Ischemic Stroke,” “AIS,” “Cerebral Infarction,” “Atrial Fibrillation,” “AFib,” “stroke,” “MR-proANP,” “Mid-regional pro-atrial natriuretic peptide,” and “proatrial natriuretic peptide.” Inclusion criteria encompassed any study focusing on MR-proANP and ischemic stroke, published up to October 15, 2023. Primary end points were newly diagnosed Afib, 90-day Modified Rankin Scale (mRS) score, and 90-day mortality. Studies were described in narrative and tabular form. Risk of bias was assessed using the ROBINS-I tool. Pooled estimates for our key end points were generated using a random effects model where appropriate. MR-proANP levels were significantly elevated in newly diagnosed Afib patients compared to no Afib patients (mean difference (MD): 134.4 pmol/l; 95% confidence interval (CI): 119.45 to 149.35,
P
< 0.0001). Unfavorable functional outcomes, as measured by mRS scores of ≥ 3 at 90 days, were associated with higher levels of MR-proANP (MD: 93.87 pmol/; 95% CI: 76.66 to 111.09,
P
< 0.0001). Elevated MR-proANP levels were also strongly correlated with increased 90-day mortality rates (MD: 164.43 pmol/; CI: 95.94 to 232.92,
P
< 0.0001). MR-proANP was significantly associated with functional outcomes, 90-day mortality, and the newly diagnosed AF. The limited number of studies included calls for further large-scale research to confirm these findings and explore the potential for expedited diagnostic procedures and targeted interventions like anticoagulant therapy.</description><subject>Atrial Fibrillation - blood</subject><subject>Atrial Natriuretic Factor - blood</subject><subject>Biomarkers - blood</subject><subject>Brain Ischemia - blood</subject><subject>Brain Ischemia - diagnosis</subject><subject>Humans</subject><subject>Ischemic Stroke - blood</subject><subject>Ischemic Stroke - diagnosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurosurgery</subject><subject>Prognosis</subject><issn>1437-2320</issn><issn>1437-2320</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMlOwzAQhi0EomV5AQ7IRy4GL1m5VRWbVBYBd8txJpCSpXiSVn17TFMQJyRLY3m--eX5CDkR_FxwHl-g4CJQjMuAccVjxVY7ZOxfYiaV5Lt_7iNygDjnXMQpF_tkpNIgjZJAjUlx_8wWrp08PNEKllAhLRs6sX0HtET7DnVpKXau_QBqmpzaqmxKayra9p1ta8BLaiiusYPadB51sCxhtUFr6AwzjanWWOIR2StMhXC8rYfk5frqdXrLZo83d9PJjFn_NcFyMKninBdZIRKpwjzJhFWQSxnIpAgTKWxqASCLVGhDq1KZhZHJs1BF3KbqkJwNqX6jzx6w07VfAqrKNND2qJWQgT9pKD0qB9S6FtFBoReurI1ba8H1t1092NXert7Y1Ss_dLrN77Ma8t-RH50eUAOAvtW8gdPztnfeAf4X-wXgAoY6</recordid><startdate>20241105</startdate><enddate>20241105</enddate><creator>Musmar, Basel</creator><creator>Salim, Hamza Adel</creator><creator>Grory, Brian Mac</creator><creator>Musmar, Fares</creator><creator>Spellicy, Samantha</creator><creator>Abdelgadir, Jihad</creator><creator>Adeeb, Nimer</creator><creator>Hasan, David</creator><general>Springer Berlin Heidelberg</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20241105</creationdate><title>MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis</title><author>Musmar, Basel ; Salim, Hamza Adel ; Grory, Brian Mac ; Musmar, Fares ; Spellicy, Samantha ; Abdelgadir, Jihad ; Adeeb, Nimer ; Hasan, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1791-dea93000fbf18235d8b1c3ed22428f5821c9ceeeb635c5c392b56adb5360c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Atrial Fibrillation - blood</topic><topic>Atrial Natriuretic Factor - blood</topic><topic>Biomarkers - blood</topic><topic>Brain Ischemia - blood</topic><topic>Brain Ischemia - diagnosis</topic><topic>Humans</topic><topic>Ischemic Stroke - blood</topic><topic>Ischemic Stroke - diagnosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurosurgery</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Musmar, Basel</creatorcontrib><creatorcontrib>Salim, Hamza Adel</creatorcontrib><creatorcontrib>Grory, Brian Mac</creatorcontrib><creatorcontrib>Musmar, Fares</creatorcontrib><creatorcontrib>Spellicy, Samantha</creatorcontrib><creatorcontrib>Abdelgadir, Jihad</creatorcontrib><creatorcontrib>Adeeb, Nimer</creatorcontrib><creatorcontrib>Hasan, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurosurgical review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Musmar, Basel</au><au>Salim, Hamza Adel</au><au>Grory, Brian Mac</au><au>Musmar, Fares</au><au>Spellicy, Samantha</au><au>Abdelgadir, Jihad</au><au>Adeeb, Nimer</au><au>Hasan, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis</atitle><jtitle>Neurosurgical review</jtitle><stitle>Neurosurg Rev</stitle><addtitle>Neurosurg Rev</addtitle><date>2024-11-05</date><risdate>2024</risdate><volume>47</volume><issue>1</issue><spage>835</spage><pages>835-</pages><artnum>835</artnum><issn>1437-2320</issn><eissn>1437-2320</eissn><abstract>In patients with acute ischemic stroke, midregional proatrial natriuretic peptide (MR-proANP) has shown promise in preliminary studies for risk stratification. The objective of this study is to evaluate the prognostic utility of MR-proANP in AIS, focusing on its ability to predict 90-day functional outcomes, mortality rates, and the presence of atrial fibrillation (Afib). A comprehensive literature search was conducted using PubMed, Web of Science, and Scopus, following PRISMA guidelines. The search strategy employed a combination of keywords and index terms including “Acute Ischemic Stroke,” “AIS,” “Cerebral Infarction,” “Atrial Fibrillation,” “AFib,” “stroke,” “MR-proANP,” “Mid-regional pro-atrial natriuretic peptide,” and “proatrial natriuretic peptide.” Inclusion criteria encompassed any study focusing on MR-proANP and ischemic stroke, published up to October 15, 2023. Primary end points were newly diagnosed Afib, 90-day Modified Rankin Scale (mRS) score, and 90-day mortality. Studies were described in narrative and tabular form. Risk of bias was assessed using the ROBINS-I tool. Pooled estimates for our key end points were generated using a random effects model where appropriate. MR-proANP levels were significantly elevated in newly diagnosed Afib patients compared to no Afib patients (mean difference (MD): 134.4 pmol/l; 95% confidence interval (CI): 119.45 to 149.35,
P
< 0.0001). Unfavorable functional outcomes, as measured by mRS scores of ≥ 3 at 90 days, were associated with higher levels of MR-proANP (MD: 93.87 pmol/; 95% CI: 76.66 to 111.09,
P
< 0.0001). Elevated MR-proANP levels were also strongly correlated with increased 90-day mortality rates (MD: 164.43 pmol/; CI: 95.94 to 232.92,
P
< 0.0001). MR-proANP was significantly associated with functional outcomes, 90-day mortality, and the newly diagnosed AF. The limited number of studies included calls for further large-scale research to confirm these findings and explore the potential for expedited diagnostic procedures and targeted interventions like anticoagulant therapy.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>39496843</pmid><doi>10.1007/s10143-024-03073-w</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1437-2320 |
| ispartof | Neurosurgical review, 2024-11, Vol.47 (1), p.835, Article 835 |
| issn | 1437-2320 1437-2320 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3124124952 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Atrial Fibrillation - blood Atrial Natriuretic Factor - blood Biomarkers - blood Brain Ischemia - blood Brain Ischemia - diagnosis Humans Ischemic Stroke - blood Ischemic Stroke - diagnosis Medicine Medicine & Public Health Neurosurgery Prognosis |
| title | MR-proANP levels in Acute ischemic stroke and clinical outcomes: a systematic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A03%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MR-proANP%20levels%20in%20Acute%20ischemic%20stroke%20and%20clinical%20outcomes:%20a%20systematic%20review%20and%20meta-analysis&rft.jtitle=Neurosurgical%20review&rft.au=Musmar,%20Basel&rft.date=2024-11-05&rft.volume=47&rft.issue=1&rft.spage=835&rft.pages=835-&rft.artnum=835&rft.issn=1437-2320&rft.eissn=1437-2320&rft_id=info:doi/10.1007/s10143-024-03073-w&rft_dat=%3Cproquest_cross%3E3124124952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3124124952&rft_id=info:pmid/39496843&rfr_iscdi=true |